Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IMPDH2 | P12268 | 4/20 | 0.56 |
| ▸ | PRMT3 | O60678 | 15/20 | 0.54 |
| ▸ | JAK2 | O60674 | 1/20 | 0.50 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.50 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14146999 | 0.87 | PRMT3 (0.60) | IMPDH2PRMT3ROCK2ROCK1 | |
| SCHEMBL20353540 | 0.85 | PRMT3 (0.61) | IMPDH2PRMT3 | |
| SCHEMBL20353543 | 0.84 | PRMT3 (0.62) | IMPDH2PRMT3 | |
| SCHEMBL1105187 | 0.83 | ULK1 (0.55) | PRMT3JAK2ROCK2ROCK1 | |
| SCHEMBL1105184 | 0.83 | GSK3B (0.57) | IMPDH2PRMT3JAK2ROCK2ROCK1 | |
| SCHEMBL11895760 | 0.80 | ROCK2 (0.60) | IMPDH2PRMT3JAK2ROCK2ROCK1 | |
| SCHEMBL11895759 | 0.80 | ROCK2 (0.60) | IMPDH2PRMT3JAK2ROCK2ROCK1 | |
| SCHEMBL1105014 | 0.80 | ROCK2 (0.60) | IMPDH2PRMT3JAK2ROCK2ROCK1 | |
| SCHEMBL1105029 | 0.80 | ULK1 (0.55) | IMPDH2PRMT3JAK2ROCK2ROCK1 | |
| SCHEMBL11896089 | 0.80 | ULK1 (0.55) | IMPDH2PRMT3JAK2ROCK2ROCK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2326623-B1 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | claimed |
| US-20210253547-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2021-08-19 | — | — | US | disclosed |
| US-11021456-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-06-01 | — | — | US | disclosed |
| US-10882840-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2021-01-05 | — | — | US | disclosed |
| US-20200223818-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2020-07-16 | — | — | US | disclosed |
| US-20200140407-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2020-05-07 | — | — | US | disclosed |
| US-20190127346-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2019-05-02 | — | — | US | disclosed |
| US-20190127346-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2019-05-02 | — | — | US | disclosed |
| US-20180170898-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2018-06-21 | — | — | US | disclosed |
| US-9884840-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2018-02-06 | — | — | US | disclosed |
| EP-2326623-B1 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS INC (US) | 2014-04-16 | — | — | EP | disclosed |
| US-8450344-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-8450344-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | AERIE PHARMACEUTICALS, INC. (US) | 2013-05-28 | — | — | US | disclosed |
| US-20120196916-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2012-08-02 | — | — | US | disclosed |
| US-20120196916-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2012-08-02 | — | — | US | disclosed |
| US-8153656-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| US-8153656-B2 | — | — | 2012-04-10 | — | — | US | disclosed |
| WO-2010011853-A2 | BETA-AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | AERIE PHARMACEUTICALS, INC. (US) | 2010-01-28 | — | — | WO | disclosed |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2010-01-28 | — | — | US | disclosed |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | ALCON INC. (CH) | 2010-01-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10882840-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20200140407-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20100022585-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20180170898-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20200223818-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20190127346-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20120196916-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-20210253547-A1 | BETA- AND GAMMA-AMINO-ISOQUINOLINE AMIDE COMPOUNDS AND SUBSTITUTED BENZAMIDE COMPOUNDS | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
| US-11021456-B2 | Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds | PRKCQ, UACA, BCAT2 | IMPDH2 522/4885PRMT3 1466/4885JAK2 641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.